New product: Daurismo (glasdegib) 25 and 100 mg film-coated tablets
Glasdegib, an inhibitor of the Hedgehog signal transduction pathway, is licensed, in combination with low-dose cytarabine, for treatment of newly diagnosed de novo or secondary acute myeloid leukaemia in adult patients who are not candidates for standard induction chemotherapy.
Source:
electronic Medicines compendium